INO Long Call Strategy

INO (Inovio Pharmaceuticals, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital.

INO (Inovio Pharmaceuticals, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $71.8M, a beta of 1.44 versus the broader market, a 52-week range of 1.03-2.98, average daily share volume of 2.3M, a public-listing history dating back to 1998, approximately 134 full-time employees. These structural characteristics shape how INO stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 1.44 indicates INO has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.

What is a long call on INO?

A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.

Current INO snapshot

As of May 15, 2026, spot at $1.31, ATM IV 190.95%, IV rank 40.04%, expected move 54.74%. The long call on INO below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 28-day expiry.

Why this long call structure on INO specifically: INO IV at 190.95% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 54.74% (roughly $0.72 on the underlying). The 28-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated INO expiries trade a higher absolute premium for lower per-day decay. Position sizing on INO should anchor to the underlying notional of $1.31 per share and to the trader's directional view on INO stock.

INO long call setup

The INO long call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With INO near $1.31, the first option leg uses a $1.31 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed INO chain at a 28-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 INO shares for the stock leg in covered calls and collars).

ActionTypeStrike / BasisPremium (est)
Buy 1Call$1.31N/A

INO long call risk and reward

Net Premium / Debit
N/A
Max Profit (per contract)
Unbounded
Max Loss (per contract)
Unbounded
Breakeven(s)
None on modeled curve
Risk / Reward Ratio
N/A

Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.

INO long call payoff curve

Modeled P&L at expiration across a range of underlying prices for the long call on INO. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use long call on INO

Long calls on INO express a bullish thesis with defined risk; traders use them ahead of INO catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.

INO thesis for this long call

The market-implied 1-standard-deviation range for INO extends from approximately $0.59 on the downside to $2.03 on the upside. A INO long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current INO IV rank near 40.04% is mid-range against its 1-year distribution, so the IV signal is neutral; the long call thesis on INO should anchor more to the directional view and the expected-move geometry. As a Healthcare name, INO options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to INO-specific events.

INO long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. INO positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move INO alongside the broader basket even when INO-specific fundamentals are unchanged. Long-premium structures like a long call on INO are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current INO chain quotes before placing a trade.

Frequently asked questions

What is a long call on INO?
A long call on INO is the long call strategy applied to INO (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With INO stock trading near $1.31, the strikes shown on this page are snapped to the nearest listed INO chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are INO long call max profit and max loss calculated?
Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the INO long call priced from the end-of-day chain at a 30-day expiry (ATM IV 190.95%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a INO long call?
The breakeven for the INO long call priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current INO market-implied 1-standard-deviation expected move is approximately 54.74%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a long call on INO?
Long calls on INO express a bullish thesis with defined risk; traders use them ahead of INO catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
How does current INO implied volatility affect this long call?
INO ATM IV is at 190.95% with IV rank near 40.04%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.

Related INO analysis